Please provide your email address to receive an email when new articles are posted on . Adults with differentiated thyroid cancer using a GLP-1 had similar risk for recurrence or progression as those ...

Health care specialists provide an overview on the nature of differentiated thyroid cancer and discuss subtypes of disease that patients may present with. Lori Wirth, MD: Hello, and welcome to Cure ...

GLP-1 receptor agonists were not associated with recurrence or progression in well differentiated thyroid cancer, supporting ...

Please provide your email address to receive an email when new articles are posted on . In an analysis of data from more than 600 survivors of differentiated thyroid cancer at a clinic in Germany, ...

A new study has shown that overall and cause-specific mortality rates in individuals in the U.S. with low-risk differentiated thyroid cancer (DTC) are low. The study is published in the peer-reviewed ...

A Sarasota Memorial specialist helped create new guidelines for treating differentiated thyroid cancer. The "2025 American Thyroid Association Management Guidelines" are the first update since 2015.

Graphical Abstract. Relative survival with and without radioiodine therapy (RAI) in intermediate risk papillary thyroid cancer (PTC) and low risk, minimally invasive follicular thyroid cancer (FTC). A ...

Fusion oncogenes, such as RET- and NTRK-gene fusions, are associated with more invasive pediatric thyroid cancers, correlating with the highest risk of metastases and a lower likelihood of achieving ...

An open-label, single-arm, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of the ATR inhibitor SC0245 in advanced solid ...

Discussion on when differentiated thyroid cancer is determined to be iodine-refractory, and how patients should be followed in this setting. Health care specialists share insight on the work-up of ...